Klegerman Lab

 

About our lab

Our lab focuses on developing innovative liposomal and molecular targeting strategies to enhance the diagnosis and treatment of cardiovascular and other diseases.

Research Interests

• We specialize in gas chromatographic-mass spectrometric gas analysis within therapeutic liposomal formulations, paving the way for more effective drug delivery systems. Additionally, our research explores molecular strategies for stem cell delivery, aiming to harness their regenerative potential for improved patient outcomes.
• Understanding the mechanisms of atherogenesis and atheroprogression is another core area of our investigation, as we seek therapeutic approaches to inhibit the progression of atherosclerosis. Through meticulous biochemical, cellular, and immunologic studies, we strive to unravel the underlying mechanisms driving atherogenesis.
• Our lab is at the forefront of immunochemical and biochemical assay development, enabling us to design robust and precise methods for detecting and analyzing key biomarkers. Furthermore, we delve into the intricate mechanisms of thrombosis and thrombolysis to uncover new avenues for therapeutic intervention.
• In response to the global pandemic, we have also focused on the development of quantitative ELISAs for characterizing antibodies specific to SARS-CoV-2 proteins. This research plays a crucial role in understanding immune responses and developing targeted diagnostics and therapeutics.

At the Klegerman Lab, we are driven by a passion for scientific exploration and the pursuit of knowledge that can translate into tangible advancements in healthcare. Our dedicated team of researchers is committed to pushing the boundaries of cardiovascular and disease-focused research, with the ultimate goal of improving patient outcomes and transforming lives.

 

About Melvin Klegerman, PhD

Dr. Klegerman received a B.A. in chemistry from the University of Illinois at Chicago in 1968 and a Ph.D. in biochemistry from Loyola University of Chicago in 1984.

For more than 40 years, he has conducted biomedical research focusing on immunochemistry, immunoassay development, and conjugation chemistry. For the past 30 years, Dr. Klegerman has been involved in a collaborative effort with cardiovascular researchers under the direction of Dr. David D. McPherson to develop targeted immunoliposomes for diagnosis and treatment of cardiovascular diseases, joining the group when they moved to UTHealth, where he now is a professor in the Division of Cardiovascular Medicine. As part of this effort, Dr. Klegerman founded two companies to develop the echogenic liposome technology into clinical products.

He is an author of 86 scientific papers, awardee of 10 patents, and co-editor of a textbook of pharmaceutical biotechnology (1992).

 

Publications

Discover a comprehensive library of research publications by visiting our PubMed link, showcasing the extensive contributions and expertise of Dr. Melvin Klegerman and his team members.

View our Publications